ResearcherPhilipps University of MarburgActive in the last 2 years
Anna I. Brichkina
Matched on ORCID iD 0000-0001-8707-9900; OpenAlex author ID A5069032488. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 1 paper
Papers 5
- Emerging concepts, hot topics, and open questions in today's pancreatic cancer research. Co-author DOI 10.1016/j.bbcan.2026.189614↗
- BAG6 restricts pancreatic cancer progression by suppressing the release of IL33-presenting extracellular vesicles and the activation of mast cells. Co-author DOI 10.1038/s41423-024-01195-1↗
- DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331854↗
- IL-17A-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts. Co-author DOI 10.1136/gutjnl-2022-327855↗
- A Quick Guide to CAF Subtypes in Pancreatic Cancer. Co-author DOI 10.3390/cancers15092614↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Matthias Lauth · 5 shared papers, 2023–2026 · strength 0.96
- Paper Emerging concepts, hot topics, and open questions in today's pancreatic cancer research. DOI 10.1016/j.bbcan.2026.189614↗
- Paper A Quick Guide to CAF Subtypes in Pancreatic Cancer. DOI 10.3390/cancers15092614↗
- Paper DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer. DOI 10.1136/gutjnl-2023-331854↗
- Corinna Ulrike Keber · 3 shared papers, 2024–2026 · strength 0.60
- Paper Emerging concepts, hot topics, and open questions in today's pancreatic cancer research. DOI 10.1016/j.bbcan.2026.189614↗
- Paper DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer. DOI 10.1136/gutjnl-2023-331854↗
- Paper BAG6 restricts pancreatic cancer progression by suppressing the release of IL33-presenting extracellular vesicles and t… DOI 10.1038/s41423-024-01195-1↗
- Magdalena Huber · 3 shared papers, 2023–2026 · strength 0.58
- Paper Emerging concepts, hot topics, and open questions in today's pancreatic cancer research. DOI 10.1016/j.bbcan.2026.189614↗
- Paper DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer. DOI 10.1136/gutjnl-2023-331854↗
- Paper IL-17A-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts. DOI 10.1136/gutjnl-2022-327855↗
- Thomas Mathias Gress · 3 shared papers, 2023–2026 · strength 0.58
- Paper Emerging concepts, hot topics, and open questions in today's pancreatic cancer research. DOI 10.1016/j.bbcan.2026.189614↗
- Paper DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer. DOI 10.1136/gutjnl-2023-331854↗
- Paper IL-17A-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts. DOI 10.1136/gutjnl-2022-327855↗
- Elke Pogge von Strandmann · 2 shared papers, 2024–2026 · strength 0.44
- Carsten Denkert · 2 shared papers, 2024 · strength 0.31
- Uta‐Maria Bauer · 1 shared paper, 2026 · strength 0.29
- Jörg Walter Bartsch · 1 shared paper, 2026 · strength 0.29
- Felix S.R. Picard · 2 shared papers, 2023–2024 · strength 0.29
- Veronika Lutz · 2 shared papers, 2023–2024 · strength 0.29
- Detlef Klaus Bartsch · 2 shared papers, 2023–2024 · strength 0.29
- Malte Buchholz · 2 shared papers, 2023–2024 · strength 0.27
- Paper BAG6 restricts pancreatic cancer progression by suppressing the release of IL33-presenting extracellular vesicles and t… DOI 10.1038/s41423-024-01195-1↗
- Paper IL-17A-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts. DOI 10.1136/gutjnl-2022-327855↗
- Viviane Ponath · 1 shared paper, 2024 · strength 0.15
- Bilal Alashkar Alhamwe · 1 shared paper, 2024 · strength 0.15
- Shiv K. Singh · 1 shared paper, 2023 · strength 0.12
- Christian Alexander Bauer · 1 shared paper, 2023 · strength 0.12
- Matthias M. Gaida · 1 shared paper, 2023 · strength 0.12
- Philipp Mayer · 1 shared paper, 2023 · strength 0.12
- Lukas Klein · 1 shared paper, 2023 · strength 0.12
- Mengyu Tu · 1 shared paper, 2023 · strength 0.12
- Robert Liefke · 1 shared paper, 2023 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.